S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
5 Semiconductor Giants: Navigating the Recent Pullback
3 Key Stocks Helping to Drive the EV Race
Breakout Alert: Coinbase's Consolidation Is About To End
You Can Follow BlackRock’s Market View for Your Money
Closing prices for crude oil, gold and other commodities
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
JPMorgan Chase, Advanced Micro Devices fall; Progressive, State Street rise, 4/12/2024
NASDAQ:IGMS

IGM Biosciences (IGMS) Stock Price, News & Analysis

$9.16
+0.80 (+9.57%)
(As of 04/12/2024 ET)
Today's Range
$8.28
$9.30
50-Day Range
$8.18
$17.36
52-Week Range
$3.81
$17.70
Volume
321,309 shs
Average Volume
209,284 shs
Market Capitalization
$538.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.89

IGM Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
84.4% Upside
$16.89 Price Target
Short Interest
Bearish
25.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
0.40mentions of IGM Biosciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$3.17 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.23) to ($3.03) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.78 out of 5 stars

Medical Sector

235th out of 923 stocks

Pharmaceutical Preparations Industry

100th out of 432 stocks

IGMS stock logo

About IGM Biosciences Stock (NASDAQ:IGMS)

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

IGMS Stock Price History

IGMS Stock News Headlines

Automatic Income (from home)
For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year.
IGM Biosciences, Inc. (IGMS)
Automatic Income (from home)
For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year.
IGMS Apr 2024 22.500 call
RBC Capital upgrades IGM Biosciences to outperform
IGM Biosciences Inc Ordinary Shares IGMS
BofA gets more bearish on IGM Biosciences, downgrades shares
See More Headlines
Receive IGMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
4/13/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IGMS
Fax
N/A
Employees
224
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$16.89
High Stock Price Target
$25.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+84.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
8 Analysts

Profitability

Net Income
$-246,420,000.00
Net Margins
-11,568.83%
Pretax Margin
-11,537.00%

Debt

Sales & Book Value

Annual Sales
$2.13 million
Book Value
$3.46 per share

Miscellaneous

Free Float
25,331,000
Market Cap
$538.52 million
Optionable
Optionable
Beta
0.26

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Fred M. Schwarzer J.D. (Age 71)
    CEO, President & Director
    Comp: $977.66k
  • Dr. Bruce A. Keyt Ph.D. (Age 70)
    Chief Scientific Officer
    Comp: $692.95k
  • Dr. Chris H. Takimoto FACP (Age 65)
    M.D., Ph.D., Chief Medical Officer
    Comp: $684.95k
  • Mr. Misbah Tahir (Age 48)
    Chief Financial Officer
    Comp: $957.6k
  • Mr. TS Harigopal
    Senior Vice President of Group Operations
  • Mr. Steven Weber (Age 48)
    Senior VP, Corporate Controller & Principal Accounting Officer
  • Mr. Paul C. Graffagnino
    Senior Vice President of Legal Affairs
  • Ms. Suzette Tauber (Age 60)
    Chief Human Resources Officer
  • Dr. Angus M. Sinclair Ph.D.
    Senior Vice President of Immuno-Oncology
  • Dr. Lisa L. Decker Ph.D. (Age 54)
    Chief Business Officer
    Comp: $528.18k

IGMS Stock Analysis - Frequently Asked Questions

Should I buy or sell IGM Biosciences stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IGM Biosciences in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IGMS shares.
View IGMS analyst ratings
or view top-rated stocks.

What is IGM Biosciences' stock price target for 2024?

8 equities research analysts have issued twelve-month price targets for IGM Biosciences' stock. Their IGMS share price targets range from $7.00 to $25.00. On average, they predict the company's share price to reach $16.89 in the next twelve months. This suggests a possible upside of 84.4% from the stock's current price.
View analysts price targets for IGMS
or view top-rated stocks among Wall Street analysts.

How have IGMS shares performed in 2024?

IGM Biosciences' stock was trading at $8.31 at the start of the year. Since then, IGMS stock has increased by 10.2% and is now trading at $9.16.
View the best growth stocks for 2024 here
.

Are investors shorting IGM Biosciences?

IGM Biosciences saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 5,220,000 shares, an increase of 9.7% from the March 15th total of 4,760,000 shares. Based on an average daily volume of 281,700 shares, the short-interest ratio is presently 18.5 days. Currently, 25.1% of the shares of the company are short sold.
View IGM Biosciences' Short Interest
.

When is IGM Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our IGMS earnings forecast
.

How were IGM Biosciences' earnings last quarter?

IGM Biosciences, Inc. (NASDAQ:IGMS) posted its earnings results on Thursday, March, 7th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.05. The business had revenue of $0.65 million for the quarter, compared to analysts' expectations of $0.95 million. IGM Biosciences had a negative trailing twelve-month return on equity of 103.20% and a negative net margin of 11,568.83%.

What ETFs hold IGM Biosciences' stock?

ETFs with the largest weight of IGM Biosciences (NASDAQ:IGMS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of IGM Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL), Carnival Co. & (CCL), Cisco Systems (CSCO), Dropbox (DBX) and Energy Transfer (ET).

When did IGM Biosciences IPO?

IGM Biosciences (IGMS) raised $125 million in an initial public offering (IPO) on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities served as the underwriters for the IPO.

How do I buy shares of IGM Biosciences?

Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IGMS) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners